Cerebral folate deficiency has no treatment
The core idea stands, but key numbers or details have changed.
TaughtWhen a genetic fault blocks folate from reaching the brain, children develop seizures, movement disorders, and severe developmental delay. It is a devastating, untreatable condition; you manage the symptoms and little else.
NowOn 10 March 2026 the FDA approved Wellcovorin (leucovorin calcium) as the first treatment for cerebral folate transport deficiency caused by variants in the FOLR1 gene. Leucovorin is a form of folate that can slip into the brain by a different route, bypassing the broken transporter.
What actually happened
The mechanism is almost elegant in its simplicity. The disease is not a shortage of folate in the body; it is a broken door into the brain, the folate receptor. Leucovorin, a reduced folate long used in cancer and rescue medicine, can enter through an alternative transporter, so giving enough of it effectively floods the brain by the back way.
The approval rests on published case reports and mechanistic data rather than a large randomized trial, because the disease is rare, and outcomes varied. So this is 'updated,' not a guaranteed fix: of the treated patients in the literature, many but not all improved, with reduced seizures and gains in movement and communication. Still, a condition taught as untreatable now has a named, approved therapy, and one built from a drug that had been sitting on the shelf for other uses the whole time.
Newsletter
Get new weekly revisions
Sources
Who was taught this
Still standard through 2026, so anyone who finished school between 1950 and 2026 learned the earlier version.